By Pushkala Aripaka

(Reuters) -AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney disease drugs, prompting London’s most valuable listed company to retain its full-year forecasts.

AstraZeneca is making big strides to achieve its goal of $80 billion in annual revenues by 2030, and is betting on its expansion plans and drug pricing deal in the U.S., its biggest market, to provide some relief from import tariffs.

Global drugmakers have pledged billions of dollars to boost their manufacturing in the United States in a bid to avoid tariffs.

AstraZeneca will also list its shares on the NYSE to gain access to a deeper capital pool.

The Anglo-Swedish drugmaker still expects full-year revenue growth of a high single-digit pe

See Full Page